Fam83F induces p53 stabilisation and promotes its activity.


Journal

Cell death and differentiation
ISSN: 1476-5403
Titre abrégé: Cell Death Differ
Pays: England
ID NLM: 9437445

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 04 01 2018
accepted: 09 01 2019
revised: 07 01 2019
pubmed: 30 1 2019
medline: 29 9 2020
entrez: 30 1 2019
Statut: ppublish

Résumé

p53 is one of the most important tumour suppressor proteins currently known. It is activated in response to DNA damage and this activation leads to proliferation arrest and cell death. The abundance and activity of p53 are tightly controlled and reductions in p53's activity can contribute to the development of cancer. Here, we show that Fam83F increases p53 protein levels by protein stabilisation. Fam83F interacts with p53 and decreases its ubiquitination and degradation. Fam83F is induced in response to DNA damage and its overexpression also increases p53 activity in cell culture experiments and in zebrafish embryos. Downregulation of Fam83F decreases transcription of p53 target genes in response to DNA damage and increases cell proliferation, identifying Fam83F as an important regulator of the DNA damage response. Overexpression of Fam83F also enhances migration of cells harbouring mutant p53 demonstrating that it can also activate mutant forms of p53.

Identifiants

pubmed: 30692643
doi: 10.1038/s41418-019-0281-1
pii: 10.1038/s41418-019-0281-1
pmc: PMC6748130
doi:

Substances chimiques

FAM83F protein, human 0
Intracellular Signaling Peptides and Proteins 0
Neoplasm Proteins 0
Tumor Suppressor Protein p53 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2125-2138

Références

Oncogene. 1999 Mar 4;18(9):1723-32
pubmed: 10208433
J Mol Biol. 2000 Jan 28;295(4):1009-21
pubmed: 10656807
Cancer Lett. 2001 Dec 10;174(1):1-15
pubmed: 11675147
Mol Cell Biol. 2001 Dec;21(24):8521-32
pubmed: 11713287
Cell. 2003 Mar 21;112(6):779-91
pubmed: 12654245
Oncogene. 2005 Apr 18;24(17):2899-908
pubmed: 15838523
BMC Cell Biol. 2009 Jun 17;10:46
pubmed: 19534768
Crit Rev Biochem Mol Biol. 2009 Nov-Dec;44(6):367-92
pubmed: 19929178
Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10038-43
pubmed: 20479273
Methods Mol Biol. 2013;962:135-46
pubmed: 23150443
Nature. 2013 Oct 17;502(7471):333-339
pubmed: 24132290
Mol Cancer Res. 2014 Aug;12(8):1156-65
pubmed: 24736947
Oncogene. 2015 Nov 12;34(46):5729-38
pubmed: 25728675
BMC Biotechnol. 2015 Oct 08;15:92
pubmed: 26450685
Front Oncol. 2015 Dec 10;5:276
pubmed: 26697411
Tumour Biol. 2016 Jul;37(7):9009-22
pubmed: 26758433
Oncotarget. 2016 Aug 9;7(32):52597-52612
pubmed: 27221039
Eur Rev Med Pharmacol Sci. 2017 Jul;21(14):3200-3206
pubmed: 28770965
Haematologica. 2018 Jan;103(1):e13-e16
pubmed: 29079597
J Exp Clin Cancer Res. 2018 Feb 15;37(1):30
pubmed: 29448954
Hum Mutat. 2018 Jul;39(7):925-933
pubmed: 29696732
Bioessays. 1993 Oct;15(10):689-90
pubmed: 7506024
Cancer Metastasis Rev. 1995 Mar;14(1):3-15
pubmed: 7606818
Cancer Res. 1996 Jun 1;56(11):2649-54
pubmed: 8653711
Cell. 1997 Feb 7;88(3):323-31
pubmed: 9039259
Trends Biochem Sci. 1997 Oct;22(10):383-7
pubmed: 9357313
FEBS Lett. 1997 Dec 22;420(1):25-7
pubmed: 9450543
Mol Cell Biol. 1998 Oct;18(10):5690-8
pubmed: 9742086

Auteurs

Mohammed Salama (M)

Karlsruhe Institute of Technology, Institute of Toxicology and Genetics, PO-box 3640, 76021, Karlsruhe, Germany.
Histochemistry and Cell Biology Department, Medical Research Institute, Alexandria University, 165 Horreya Avenue, Hadara, Alexandria, Egypt.

Diego Benitez-Riquelme (D)

Karlsruhe Institute of Technology, Institute of Toxicology and Genetics, PO-box 3640, 76021, Karlsruhe, Germany.

Seham Elabd (S)

Karlsruhe Institute of Technology, Institute of Toxicology and Genetics, PO-box 3640, 76021, Karlsruhe, Germany.
Human Physiology Department, Medical Research Institute, Alexandria University, 165 Horreya Avenue, Hadara, Alexandria, Egypt.

Leonel Munoz (L)

Karlsruhe Institute of Technology, Institute of Toxicology and Genetics, PO-box 3640, 76021, Karlsruhe, Germany.
Faculty of Medicine, University of Valparaiso, Valparaiso, Chile.

Ping Zhang (P)

Karlsruhe Institute of Technology, Institute of Toxicology and Genetics, PO-box 3640, 76021, Karlsruhe, Germany.
Ludwig Institute for Cancer Research, University of Oxford, Oxford, OX3 7DQ, UK.

Matthias Glanemann (M)

Klinik fuer Allgemeine Chirurgie, Universitaetsklinikum des Saarlandes, Kirrberger Str., 66421, Homburg, Germany.

Maria Caterina Mione (MC)

Karlsruhe Institute of Technology, Institute of Toxicology and Genetics, PO-box 3640, 76021, Karlsruhe, Germany.
Department of Cellular, Computational and Integratrive Biology (CIBIO), University of Trento, Via Sommarive 9, Trento, Italy.

Robert Goldin (R)

Department of Cellular Pathology, Clarence Wing, St. Mary's Campus, London, UK.

Thierry Soussi (T)

Sorbonne Université, UPMC Univ Paris 06, F-75005, Paris, France.
Department of Oncology-Pathology, Cancer Center Karolinska (CCK), Karolinska Institutet, Stockholm, Sweden.
INSERM, U1138, Équipe 11, Centre de Recherche des Cordeliers, Paris, France.

Gary Davidson (G)

Karlsruhe Institute of Technology, Institute of Toxicology and Genetics, PO-box 3640, 76021, Karlsruhe, Germany.

Christine Blattner (C)

Karlsruhe Institute of Technology, Institute of Toxicology and Genetics, PO-box 3640, 76021, Karlsruhe, Germany. christine.blattner@kit.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH